Oxford Cannabinoid Technologies Holdings (OCTP) – the company developing prescription cannabinoid medicines – is expanding its research and development plans into oncology. The decision comes after it identified a potential first in class immunotherapy agent for solid tumour treatment.
Registered office
11 Lyons Walk
Shaftesbury
Dorset
SP7 8JF
office@icr-global.org